Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- PARKINSONISM & RELATED DISORDERS51 · pp.67 · 2018
- 피인용
- Web of Science 25Scopus 29
- FWCI (Scopus)
- 1.08
- JCR IF
- JCR 2017 4.721
- ISSN
- 1353-8020
저자
- 박경준제1저자Department of Nuclear Medicine, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, South Korea
- 신혜경Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, South Korea
- 김은주Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, South Korea
- 이재혁Department of Neurology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea
- Lyoo, Chul HyoungDepartment of Neurology, Gangnam Severance Hospital, Yonsei University Medical College, Seoul, South Korea
- Son, JongsangSensory Motor Performance Program, Rehabilitation Institute of Chicago, Chicago, United States
- 이명준교신저자Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Busan, South Korea
초록
Introduction: Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists. Methods: Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on I-123-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane (I-123-FP-CIT) single positron emission computed tomography (SPECT). We defined BMI loss as a reduction in BMI value > 5% of baseline, and categorized the PD patients into 2 subgroups (patients with and without BMI loss). Linear mixed model (LMM) analysis was employed to compare the progression of striatal dopaminergic degeneration. Results: In LMM analyses, BMI values in PD patients were not correlated with clinical severities of parkinsonian motor deficits, cognitive impairment and depressive mood. However, BMI values were positively associated with changes in striatal I-123-FP-CIT binding over 24 months (caudate nucleus, estimate = 9.37 x 10(-3), p = 0.009; putamen, estimate = 7.04 x 10(-3), p = 0.031). Patients with BMI loss exhibited greater deterioration of striatal dopaminergic activity than those without (caudate nucleus, estimate = 3.35 x 10(-3), p = 0.008; putamen, estimate = 2.34 x 10(-3), p =0.025). Conclusion: Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD. (C) 2018 Elsevier Ltd. All rights reserved.
키워드
Parkinson diseaseWeight lossBody mass indexI-123-FP-CITSPECTBODY-MASS INDEXPROGRESSIONPREDICTORSDEPRESSIONSYMPTOMSSURVIVALCOHORT
식별자
- Scopus EID
- 2-s2.0-85042701333
- WoS UID
- 000438660600012



로그인
연구물 목록으로